Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

• Published in: Journal of clinical oncology Vol. 41; no. 2; pp. 154 - 162
• Main Authors: McLaughlin, P, Grillo-López, A J, Link, B K, Levy, R, Czuczman, M S, Williams, M E, Heyman, M R, Bence-Bruckler, I, White, C A, Cabanillas, F, Jain, V, Ho, A D, Lister, J, Wey, K, Shen, D, Dallaire, B K
• Format: Journal Article
• Language: English
• Published: United States 10.01.2023

The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies. This was a multi...